NAN342K Mutation Enhances the Pathogenicity of Influenza B Virus in Mice

Qi Chen, Xiaohao Xu, Min Tan, Lei Yang, Dayan Wang, Yuelong Shu, Wenfei ZhuZoonoses 2023 · DOI

Abstract

Objective: Influenza B virus is a significant respiratory pathogen responsible for seasonal influenza. In recent years, the B/Yamagata lineage has demonstrated a rapid increase, predominantly featuring the neuraminidase (NA) N342K mutation. This study determined the impact of the NA N342K mutation on the pathogenicity of influenza B virus and elucidated the underlying mechanisms.

Methods: Gene fragments with specific mutations were generated using site-directed mutagenesis PCR, resulting in recombinant viruses (rAH127 and rAH127/NA N342K). C57BL/6 mice were infected to evaluate the impact of amino acid mutations on virus pathogenicity. Body weight, survival rate, virus replication, and lung pathology were compared among the groups. NA enzyme activity was assessed to determine the mechanisms underlying the effects of amino acid mutations on the pathogenicity of influenza B virus.

Results: The NA N342K mutant virus exhibited significantly increased NA enzyme activity (3.19-fold) and viral replication capacity in MDCK cells (6.76-fold) compared to wild-type virus. These changes led to enhanced pathogenicity in mice, characterized by severe weight loss, increased mortality, and heightened lung tissue inflammation.

Conclusions: The NA N342K mutation likely enhances virus replication and pathogenicity by increasing NA enzyme activity. These findings contribute to understanding the molecular mechanisms underlying influenza B virus pathogenicity and have implications for targeted therapeutic strategies.

Introduction

Influenza B virus (IBV) is a major respiratory pathogen, contributing to up to 30% of seasonal influenza cases globally. While often overshadowed by Influenza A (H1N1 and H3N2), IBV poses a severe threat, particularly to children, where it can cause higher mortality rates. The virus circulates as two distinct lineages: B/Victoria and B/Yamagata.

Figure 1: Distribution of influenza virus types and lineages in China (2012–2019), showing the fluctuating prevalence of the B/Yamagata (blue) and B/Victoria (red) lineages.

In recent years, the B/Yamagata lineage has evolved rapidly. Surveillance data identified a specific mutation at position 342 of the Neuraminidase (NA) protein—changing the amino acid from Asparagine (N) to Lysine (K)—which has become dominant since 2016. This study investigates whether this evolutionary shift was a neutral drift or if it significantly enhanced the virus's pathogenicity.

Methods

The researchers employed a multi-disciplinary approach combining epidemiological analysis, reverse genetics, and animal models. They analyzed 723 complete NA sequences of B/Yamagata viruses from the GISAID database and surveillance data from the Chinese National Influenza Center (2012–2019).

Using an 8-plasmid reverse genetics system, they generated two recombinant viruses: a wild-type (rAH127) and a mutant version ($rAH127/NA_{N342K}$). In vitro assays measured viral growth kinetics in MDCK cells and NA enzymatic activity. Finally, C57BL/6 mice were infected to compare weight loss, survival rates, viral lung titers, and lung pathology.

Results

Evolutionary Dominance of N342K

The $N342K$ mutation rapidly outcompeted previous variants, suggesting a strong selective advantage. As shown in the surveillance data, the proportion of viruses carrying the Lysine (K) at position 342 rose sharply starting in 2017, becoming the nearly universal variant by 2018.

Figure 2: (C) Total number of B/Yamagata NA sequences analyzed per year. (D) Percentage of amino acids at position 342 of the NA protein, illustrating the rapid dominance of the N342K mutation (pink) starting in 2017.

Molecular Mechanism: The "Exit" Strategy

Neuraminidase's primary function is to cleave sialic acid receptors, allowing newly formed virus particles to release from host cells. The 342 site is physically close to the enzyme's active site. The $N342K$ mutation was found to increase NA enzymatic activity by 3.19-fold. This enhanced "exit" strategy allowed the mutant virus to replicate much more aggressively, reaching peak titers in cell culture that were 6.76 times higher than the wild-type at 48 hours post-infection.

Enhanced Pathogenicity in Mice

The increased replication capacity translated into significantly higher disease severity in vivo. In the mouse model:

  • Mortality: At a high dose ($10^7$ $TCID_{50}$), the wild-type virus caused zero deaths, while 60% of mice infected with the $N342K$ mutant died within five days.
  • Weight Loss: Mice infected with the mutant virus showed rapid and severe weight loss, reaching a nadir at 4 days post-infection.
  • Lung Pathology: Histological analysis confirmed that the mutant virus induced significantly more severe lung tissue inflammation (bronchopneumonia) compared to the wild-type.

Discussion

This study demonstrates that the $NA_{N342K}$ mutation acts as a "pathogenicity booster" for the B/Yamagata lineage. By supercharging the neuraminidase enzyme, the mutation enables faster viral spread and more extensive tissue damage.

While the mouse model is a robust proxy, the exact impact on human populations requires further clinical correlation. Additionally, while higher replication often correlates with higher shedding and transmissibility, this remains to be proven for $N342K$. As IBV re-emerges following the COVID-19 pandemic, monitoring these specific mutations is critical for effective vaccine strain selection and the development of targeted therapeutic strategies.

Conclusion

The $NA_{N342K}$ mutation significantly enhances the replication and pathogenicity of Influenza B virus by increasing neuraminidase activity. These findings provide a molecular basis for the recent evolutionary dominance of this variant and highlight the importance of genomic surveillance in managing seasonal influenza outbreaks.

Summary updated

Abstract

Objective: Influenza B virus is a significant respiratory pathogen responsible for seasonal influenza. In recent years the B/Yamagata lineage has demonstrated a rapid increase, predominantly featuring the neuraminidase (NA) N342K mutation. This study determined the impact of the NA N342K mutation on the pathogenicity of influenza B virus and elucidate the underlying mechanisms. Methods: Gene fragments with specific mutations were generated using site-directed mutagenesis PCR, resulting in recombinant viruses (rAH127 and rAH127/NA N342K ). C57BL/6 mice were infected to evaluate the impact of amino acid mutations on virus pathogenicity. Body weight, survival rate, virus replication, and lung pathology were compared among the groups. NA enzyme activity was assessed to determine the mechanisms underlying the effects of amino acid mutations on the pathogenicity of influenza B virus. Results: The NA N342K mutant virus exhibited significantly increased NA enzyme activity (3.19-fold) and viral replication capacity in MDCK cells (6.76-fold) compared to wild-type virus. These changes led to enhanced pathogenicity in mice, characterized by severe weight loss, increased mortality, and heightened lung tissue inflammation. Conclusions: The NA N342K mutation likely enhances virus replication and pathogenicity by increasing NA enzyme activity. These findings contribute to understanding the molecular mechanisms underlying influenza B virus pathogenicity and have implications for targeted therapeutic strategies.
BibTeX
@inproceedings{chen2023nan,
  author = {Qi Chen and Xiaohao Xu and Min Tan and Lei Yang and Dayan Wang and Yuelong Shu and Wenfei Zhu},
  title = {{NAN342K Mutation Enhances the Pathogenicity of Influenza B Virus in Mice}},
  booktitle = {Zoonoses},
  year = {2023},
  doi = {10.15212/zoonoses-2023-0013},
}
Figure